MeSH term
Frequency | Condition_Probility | Animals | 5 | 0.0 |
Breast Neoplasms/*metabolism | 3 | 1.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Female | 17 | 0.0 |
Humans | 33 | 0.0 |
Mice | 3 | 0.0 |
Neuregulin-1/*pharmacology | 10 | 58.0 |
Phosphorylation | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 19 | 0.0 |
Tumor Cells, Cultured | 12 | 0.0 |
Male | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Genes, erbB-2 | 2 | 2.0 |
Research Support, Non-U.S. Gov't | 21 | 0.0 |
Transfection | 3 | 0.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Amino Acid Sequence | 3 | 0.0 |
Cell Division/drug effects | 6 | 0.0 |
Cell Line | 3 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Signal Transduction | 6 | 0.0 |
Cell Movement/drug effects | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects/*physiology | 2 | 8.0 |
Acetylation | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Histones/metabolism | 2 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Breast Neoplasms | 3 | 1.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Ligands | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Colonic Neoplasms | 2 | 1.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Protein Binding | 4 | 0.0 |
Breast Neoplasms/pathology | 2 | 1.0 |
Carrier Proteins/*pharmacology | 2 | 4.0 |
Glycoproteins/*pharmacology | 3 | 3.0 |
*Neuregulin-1 | 5 | 19.0 |
Receptor, erbB-3 | 4 | 4.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Receptor, erbB-2/*metabolism | 2 | 1.0 |
Androstadienes/pharmacology | 2 | 0.0 |
Cell Line, Tumor | 5 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Disease Progression | 2 | 0.0 |
Neuregulin-1/*physiology | 2 | 22.0 |
Receptor, erbB-3/*metabolism | 2 | 9.0 |
Time Factors | 3 | 0.0 |
Breast Neoplasms/*physiopathology | 2 | 9.0 |
Comparative Study | 2 | 0.0 |
Drug Interactions | 2 | 0.0 |
